X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

CXCR5 antibody

RRID:AB_394337

Antibody ID

AB_394337

Target Antigen

CXCR5 human

Proper Citation

(BD Biosciences Cat# 552118, RRID:AB_394337)

Clonality

monoclonal antibody

Reference

PMID:27693350

Comments

Flow cytometry

Host Organism

rat

Vendor

BD Biosciences Go To Vendor

Cat Num

552118

Publications that use this research resource

Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells.

  • Boice M
  • Cell
  • 2016 Oct 6

Literature context:


Abstract:

The HVEM (TNFRSF14) receptor gene is among the most frequently mutated genes in germinal center lymphomas. We report that loss of HVEM leads to cell-autonomous activation of B cell proliferation and drives the development of GC lymphomas in vivo. HVEM-deficient lymphoma B cells also induce a tumor-supportive microenvironment marked by exacerbated lymphoid stroma activation and increased recruitment of T follicular helper (TFH) cells. These changes result from the disruption of inhibitory cell-cell interactions between the HVEM and BTLA (B and T lymphocyte attenuator) receptors. Accordingly, administration of the HVEM ectodomain protein (solHVEM(P37-V202)) binds BTLA and restores tumor suppression. To deliver solHVEM to lymphomas in vivo, we engineered CD19-targeted chimeric antigen receptor (CAR) T cells that produce solHVEM locally and continuously. These modified CAR-T cells show enhanced therapeutic activity against xenografted lymphomas. Hence, the HVEM-BTLA axis opposes lymphoma development, and our study illustrates the use of CAR-T cells as "micro-pharmacies" able to deliver an anti-cancer protein.

Funding information:
  • NIMH NIH HHS - T32 MH019983(United States)